Robinhood reports August 2025 customer and trading metrics
Investing.com - Guggenheim raised its price target on Savara (NASDAQ:SVRA) to $11.00 from $8.00 on Tuesday, while maintaining a Buy rating on the stock. The company, currently valued at $811 million, has seen impressive momentum with a 48% gain over the past six months. According to InvestingPro data, analyst targets range from $7 to $16, reflecting strong growth potential.
The price target increase follows several positive developments for the company, including an update on manufacturing for its drug Molbreevi. Savara announced during its Q2 2025 earnings that it has reached alignment with the FDA on Biologics License Application (BLA) resubmission requirements. The company maintains a strong financial position, with InvestingPro analysis showing more cash than debt and a healthy current ratio of 11.08.
The company has switched its primary drug product manufacturer from GEMA to Fujifilm Diosynth Biotechnologies, which Guggenheim views positively due to Fujifilm’s more established FDA track record. Savara now expects to resubmit its BLA in December 2025, with potential FDA approval in August 2026 if granted Priority Review.
Savara also released results from a new claims analysis suggesting approximately 50% more patients in the US are diagnosed with autoimmune pulmonary alveolar proteinosis (aPAP) than previously estimated, prompting Guggenheim to adjust its aPAP prevalence estimates.
The company has narrowed its potential pricing range for Molbreevi to $400,000-$500,000 on a list price basis, up from its previous range of $300,000-$500,000, leading Guggenheim to increase its launch list price estimate to $425,000 and project peak probability-of-success adjusted annual US Molbreevi sales of $962 million, up from $680 million.
In other recent news, Savara Inc. announced the results from its Phase 3 IMPALA-2 clinical trial for molgramostim inhalation solution, highlighting significant improvements in pulmonary gas transfer for autoimmune pulmonary alveolar proteinosis (aPAP) patients. The trial results, set to be published in the New England Journal of Medicine, demonstrated notable improvements compared to placebo over 24 weeks. Additionally, JMP Securities reiterated its Market Outperform rating and maintained an $8.00 price target, citing the robust findings from the trial. H.C. Wainwright also upgraded Savara’s stock rating to Buy, increasing the price target to $8.00, following an updated health claims record analysis for aPAP patients. This comes after a previous upgrade from Neutral to Buy due to Savara’s alignment with the FDA on data requirements for resubmitting its Biologics License Application for Molbreevi. Furthermore, Savara’s partner, TrilliumBiO, is set to present new diagnostic tool research for aPAP at the European Respiratory Society Congress 2025. This presentation will focus on a dried serum assay designed to detect GM-CSF antibodies, which are crucial for diagnosing aPAP. These developments mark significant progress in Savara’s efforts to address the needs of aPAP patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.